A phase II study of 2nd-line FOLFIRI+aflibercept in patients with colorectal cancer resistant to anti-EGFR chemotherapy (HGCSG1801)

ABSTRACT: Interventions: FOLFIRI+aflibercept therapy is administered.;D004358;chemotherapy Primary outcome(s): progression-free survival rate at six months (PFS rate at 6 months) Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2613784 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR